Attanasio et al., Clin Endocrinol (Oxf) 2002
:
Only the group classed as GH deficient by both criteria had a mean IGFBP-3 less than -2 SDS and both IGF-I SDS and IGFBP-3 SDS increased steadily across the four groups
van der Kaay et al., Growth Horm IGF Res 2009
(Growth Disorders) :
During GH treatment, children with C ( -202 ) /C ( -185 ) haplotype showed a significantly greater increase in IGFBP-3 SDS and in height SDS than children with A ( -202 ) /C ( -185 ) haplotype, resulting in similar IGFBP-3 levels and similar height SDS after 12 months of GH treatment